http://www.asm.org/modules/mod_image_show_gk4/cache/mSphere Direct herogk-is-651.pnglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Podcast Hero Banner3gk-is-651.pnglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Microbe Online Program Plannergk-is-651.pnglink
http://www.asm.org/modules/mod_image_show_gk4/cache/AAAS Fellows Bannergk-is-651.jpglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Read New JMBE Bannergk-is-651.jpglink
0 1 2 3 4
Progress bar
20-01-2017mSphere Direct
20-01-2017Podcast banner
20-01-2017AAAS Fellows
20-01-2017Read new JMBE
Become a member today!
JOIN/RENEW
Submit to an ASM Journal
SUBMIT
Attend ASM Biothreats Meeting
REGISTER

 

Dr. Hazuda's research on the HIV-1 integrase enzyme catalyzed the identification of viral integration inhibitors, the validation of this mechanism in vivo, and the understanding of mechanisms of resistance. These accomplishments resulted in the development and approval of raltegravir (tradename ISENTRESS), the first integrase inhibitor licensed for treatment of HIV-1 infection.

TPL_asm2013_SEARCH

91033